Annikki de Niet 1 , Louis Jansen 1 , Femke Stelma 1 , Sophie B Willemse 1 , Sjoerd D Kuiken 2 , Sebastiaan Weijer 3 , Carin M J van Nieuwkerk 4 , Hans L Zaaijer 5 , Richard Molenkamp 6 , R Bart Takkenberg 1 , Maarten Koot 7 , Joanne Verheij 8 , Ulrich Beuers 1 , Hendrik W Reesink 9
May 15 2017
Antiviral treatment is currently not recommended for patients with chronic hepatitis B with a low viral load. However, they might benefit from acquiring a functional cure (hepatitis B surface antigen [HBsAg] loss with or without formation of antibodies against hepatitis B surface antigen [anti-HBs]). We assessed HBsAg loss during peg-interferon-alfa-2a (peg-IFN) and nucleotide analogue combination therapy in patients with chronic hepatitis B with a low viral load.